Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Contract manufacturer (CMO) Cytovance Biologics will provide process manufacturing and cGMP services to SELK2, an antibody being developed by Selexys Pharmaceuticals, a clinical stage biopharmaceutical firm.
Subscribe to our email newsletter
Selexys develops drugs that target certain underlying mechanisms of inflammatory diseases and cancer.
SELK2 is an investigational humanized monoclonal antibody designed to treat Crohn’s Disease and Multiple Myeloma.
Under the deal, Cytovance Biologics will also offer scale up services for SELK2 in support of a Phase I human clinical trial.
Selexys president and CEO Scott Rollins said with this agreement, the company continues its longstanding relationship with Cytovance.
"Cytovance has been an integral part in helping us advance our clinical trial programs," Rollins said.
"We look forward to working with the company’s team of professionals on this new product for the treatment of inflammatory diseases and cancer."
Cytovance Biologics president and chief executive officer Darren Head said the company has been a manufacturing provider for Selexys since 2010 and welcomes this new project of SELK2 drug product for Phase I clinical materials.
"We are proud to be an established partner with Selexys and support them in finding an effective therapy for Crohn’s Disease that affects nearly 500,000 patients in the U.S," Head said.
Selexys is focused on development of therapeutics for the treatment of inflammation, thrombosis and cancer metastasis across a broad range of severe diseases.
The company is also developing an antibody directed against PSGL-1 for the treatment of Crohn’s disease, multiple myeloma, and other inflammatory disorders.